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Several studies, mostly conducted on cancer cell lines, however support the idea that a diversity of plasmamem-
brane channels participates in the remodeling of Ca2+ homeostasis, which regulates various cancer hallmarks
such as uncontrolled multiplication and increase in migration and invasion abilities. However few is still under-
stood concerning the intracellular signaling cascades mobilized by calcium inﬂux participating to cancer cell be-
havior. This review intends to gather some of these pathways dependent on plasmamembrane calcium channels
and described in prostate, breast and lung cancer cell lines. In these cancer cell types, the calcium channels in-
volved in calcium signaling pathways promoting cancer behaviors are mostly non-voltage activated calcium
channels and belong to the TRP superfamily (TRPC, TPRPV and TRPM families) and the Orai family. TRP and
Orai channels are part of many signaling cascades involving the activation of transmembrane receptors by extra-
cellular ligand from the tumor environment. TRPV can sense changes in the physical and chemical environment
of cancer cells and TRPM7 are stretch activated and sensitive to cholesterol. Changes in activation and or expres-
sion of plasma-membrane calcium channels affect calcium-dependent signaling processes relevant to tumori-
genesis. The studies cited in this review suggest that an increase in plasma membrane calcium channel
expression and/or activity sustain an elevated calcium entry (constitutive or under the control of extracellular
signals) promoting higher cell proliferation and migration in most cases. A variety of non-voltage-operated cal-
cium channels display change expression and/or activity in a same cancer type and cooperate to the sameprocess
relevant to cancer cell behavior, or can be involved in a different sequence of events during the tumorigenesis.
This article is part of a Special Issue entitled: Membrane channels and transporters in cancers.
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Tumorigenesis occurs as a result of mutations driving the transfor-
mation of cells and the conferring of cancer-speciﬁc hallmarks [1],
such as self-sufﬁciency in growth signals and evasion of apoptosis.
Many known mutations lead to the formation of oncogenes, which
code for protein kinases [2]. Changes in protein kinase activity that inte-
grate with numerous signaling pathways have major consequences for
a variety of processes that drive the cell's fate. Similarly, changes in
cytosolic free Ca2+ concentration ([Ca2+]i) represent a ubiquitous
signaling mechanism, which integrates with other signal-transduction
cascades and controls a variety of cellular processes [3]. As for protein
kinase, alterations of calcium signaling and homeostasis induce
wide ranging consequences, and it is not surprising that some Ca2+-
mediated signaling pathways are implicated in tumorigenesis and
tumor progression (refs. [4,5]).
The free calcium ion concentration is tightly and precisely controlled
in cellular compartments, in order to generate intracellular calcium sig-
nals with various amplitudes, as well as different temporal and spatial
properties. This precise control is essential for differential modulation,
in an individual cell, of various signaling pathways and intracellular
Ca2+-regulated proteins involved in speciﬁc cellular processes. These
include regulation of the cell cycle, proliferation, apoptosis, gene tran-
scription, and cell migration [3]. Since all these functions are relevant
to tumorigenesis, the remodeling of intracellular Ca2+ homeostasis
and of Ca2+ signals is thought to be a crucial event in leading to, or
maintaining, malignant phenotypes. Indeed, tumor transformation is
associatedwith a major rearrangement of Ca2+-transportingmolecules
(changes in expression and/or function), which participates with other
signaling pathways. This may result in enhanced survival (evasion of
apoptosis), excessive proliferation, malignant angiogenesis, cell migra-
tion and metastasis (refs. [6,7]). Various modiﬁcations of Ca2+-
transporting molecules and of proteins regulating calcium homeostasis
(the Ca2+-toolkit) have been observed and suggested. Among these are
mutations; changes in expression level or in subcellular localization;
and regulation by other signaling pathways. These changes can lead to
modiﬁcations of Ca2+ concentration in different cellular compartments
and microdomains, as well as changes in intracellular Ca2+ signal
patterns. This can contribute to a new cell fate by changing the regula-
tion of various calcium-dependent effectors involved in key intracellular
signaling pathways (ref. [7]).
2. Plasma membrane calcium channels and transporters
Among the Ca2+-transportingmolecules that are affected in various
cancer cells, the Ca2+ -toolkit at the plasma membrane is essential to
control Ca2+ entry and extrusion. It may be of great interest as a poten-
tial therapeutic target or a prognostic biomarker (refs. [8,9]). Plasma
membrane channels support the entry of Ca2+ along its concentration
gradient across the plasma membrane into the cell. Various calcium
channels, such as voltage-gated Ca2+ channels (Cav family), can be in-
volved in this Ca2+ inﬂux. The expression of this family of proteins is
a characteristic of “excitable cells,” and these channels do require depo-
larization of the plasmamembrane (PM) for activation. However, some
of these, such as members of the low voltage-activated (low threshold
of activation) Cav3 subfamily, are expressed in a number of cancer cell
lines, and they modulate proliferation (ref. [9]). Despite Cav expression,
Ca2+ entry in non-excitable cells mostly occurs through non-voltage-
gated channels. These include ligand-gated channels (P2X purinergic
ionotropic receptor families, for instance); receptor-operated channels
(ROC) or secondary messenger-operated channels linked to GPCR acti-
vation (SMOC: Orai family and members of TRP (Transient Receptor
Potential) superfamily of channels); store-operated channels (SOCE:
Orai family and members of TRPC (TRP Canonical) subfamily of chan-
nels); and stretch-operated channels (members of TRP superfamily of
channels). Numerous studies have shown that one or several of thesePM Ca2+-permeable channels are modiﬁed in expression and/or activi-
ty in different cancer cells, and play a role in most of the pathophysio-
logical processes driving the malignant phenotype (refs. [6,7]). In
addition to the PM Ca2+ channels, changes in Ca2+-transporters such
as PMCA (PlasmaMembrane Calcium ATPase) and Na+/Ca2+ exchang-
er have also been reported to be involved in the Ca2+ homeostasis of
cancer cells, and to tumorigenesis (refs. [6,7]). In addition to PMCA
Ca2+, other intracellular transporters, in particular SERCA, have also
been described as playing critical roles in tumor cell fate.
Among PM channels, TRP protein expression is modiﬁed during
cancer progression, and can represent diagnostic/prognostic markers
(ref. [10]). Mammalian TRP proteins assemble as homo- or hetero
tetramers and build non-selective Ca2+-permeable cation channels
(refs. [11,12]). TRP channels enable cells to sense changes in their
local environment, and can be stimulated by a variety of different stim-
uli. These can be physical (temperature, osmotic pressure, or mechani-
cal stress); or chemical (pH, ROS, pO2, growth factors and cytokines);
and are key elements in the tumor environment. TRP proteins, the ex-
pression of which is frequently changed, are members of the TRPC
(TRPC1 and 6), TRP vanilloid (TRPV2 and 6), and TRP Melastatin
(TRPM7 and 8) subfamilies. Some TRP channels, such as TRPV2, respond
to diverse stimuli that include heat, mechanical stress, and growth fac-
tors. The activation mechanism of TRPM subfamily channels is equally
varied: TRPM8 is activated upon cooling, and is sensitive to intracellular
pH, while TRPM7 is regulated by intracellular concentration of Mg2+
and by mechanical stimuli. TRPC channels are activated through path-
ways coupled to the activation of the PhosphoLipase C (PLC), and can
support Receptor-Operated Ca2+ Entry (ROCE) [13]. Interestingly,
TRPC1 and TRPC6 have also been suggested to be activated by PM
stretch. Moreover, TRPC1 and TRPC4 have been shown to support rela-
tively non-selective cation currents that contribute to Store-Operated
Calcium Entry (SOCE) [13]. SOCE is calcium entry stimulated by deple-
tion of internal Ca2+ stores following calcium release. It is dependent
upon the ER (Endoplasmic Reticulum) Ca(2+) sensor protein STIM1
(STromal Interaction Molecule 1). STIM1, when localized at the reticu-
lummembrane, senses the Ca2+ in the lumina of the endoplasmic retic-
ulum and is stimulated by store depletion. STIM1 activates SOCE
through its interaction with Orai1 channels at the PM (ref. [14]). Orai1
is a calcium channel widely expressed in various cell types, and forms
the pore of calcium selective channels thatmediate SOCE. STIM1 also in-
teracts with TRPC1 [15], and TRPC1-Orai1-STIM1 ternary complex has
been described as contributing to functionally distinct SOCE [16].
Numerous examples of Ca2+-toolkit remodeling and Ca2+
mishandling are provided by the literature, and some of these changes
have been proposed to be signiﬁcant drivers promoting and maintain-
ing the tumor phenotype. Currently, the Ca2+-permeable channels of
the PM represent the more promising candidates for pharmacological
therapeutic targets. Modulators of the Ca2+ toolkit have been shown
to reduce or reverse malignant phenotype in various cancer cell lines
(refs. [7,9]). However, the poor selectivity of pharmacological drugs
available constitutes a major limitation for clinical use. Moreover, the
ubiquitous role of Ca2+ signaling may suggest that targeting the PM
Ca2+ channels will exhibit poor selectivity over cancer cells. In this con-
text, inhibiting ormodulating some of the Ca2+ channels which are sig-
niﬁcantly upregulated in cancer cells, and have a restricted tissue
distribution, could prevent systemic consequences. The study of calci-
um homeostasis and the Ca2+ toolkit in cancer cells is a rather novel
area of research, and most of the data available has been obtained in
in vitro cell lines and a few primary human cancer cells. Although the
role of the PM Ca2+ channels is just beginning to be understood, exper-
imental evidence has suggested involvement in key determinantmalig-
nant processes in cellular models from tissues such as breast, prostate,
lung and colon, where some of the most common cancers develop.
The present review focuses on the role of the PM Ca2+-channels in
regulating proliferation or migration and metastasis in cancer cell
lines. Numerous reviews have presented global changes of the Ca2+
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studies that provide a clear functional role of PMCa2+-channels and de-
scribe downstream intracellular signaling pathways leading to changes
in proliferation or migration in three common cancer types: prostate,
breast, and lung.3. Ca2+ and proliferation
It is well-known that cell proliferation is dependent on the cell cycle,
which consists of four primary phases: G1, the ﬁrst gap phase; S phase,
in which DNA synthesis occurs; G2, the second gap phase; andMphase,
or mitosis, in which the chromosomes and cytoplasmic components are
divided between two daughter cells. The transitions between these dif-
ferent phases are tightly controlled, and checkpoints during the cell
cycle determine whether the cell proceeds to the next phase [17].
These checkpoints have been shown to be dependent on calcium. Vari-
ations in Ca2+i are known to play a pivotal role throughout the cell
cycle, during the early phase G1 and at the G1/S and G2/M transitions
(ref. [5]): Several studies have established that cell proliferation and di-
vision are dependent on extracellular Ca2+, and that increases in basal
Ca2+i or a transient increase in Ca2+ is involved in cell cycle progression
and cell proliferation (refs. [18,19]). During the cell cycle, Ca2+ tran-
sients have been characterized during G1 and mitosis [20]. Ca2+ is
required early in G1, as cells re-enter the cell cycle, to promote the acti-
vation of AP1 (FOS and JUN) transcription factors, c-AMP-responsive el-
ement binding (CREB) protein, and the nuclear factor of activated T-cell
(NFAT). Calcium plays a key role through these factors in coordinating
expression of cell cycle regulators such as the D-type cyclins, which
are required for the activation of cyclin-dependent kinase 4 complexes.
The assembly of D-K4 and E-K2 complexes is also dependent on the
concentration of Ca2i, and this activation controls the phosphorylation
and inactivation of retinoblastoma (RB1), which is involved in entry
into S phase. The initiation of the centrosomal duplication at the G1/S
phase is also dependent on Ca2+ and on calmodulin (CaM), CaM kinase
II (CaMK) and the centrosomal protein CP110. Calcium/CaM/CaMK
pathways were shown to be necessary for cell cycle progression (ref.
[18]). CaMwas shown to be required at two points, early after mitogen-
ic stimulation and late in G1 near the G1/S boundary [21,22]. The point
in late G1 when Ca2+/CaM is required was before the restriction point
and pRb phosphorylation [23]. The calcium/calcineurin pathway is
also implicated in the regulation of cell cycle checkpoints. Calcineurin,
a calcium-dependent phosphatase, also plays a major role in progres-
sion through G1 and S phases, and was shown to regulate Cyclins A
and E [24], as well as accumulation of cyclin D1 [18]. Calcineurin is
also very well-known to activate NFAT, and a demonstrated link with
MYC [9,25] regulating cyclins E and E2F provides another connection
between calcium-dependent pathways and proliferation.
The calcium/calcineurin/NFAT pathway is one of the major routes
that can be activated by calcium entry through plasmamembrane calci-
um channels. For instance, TRPC6 and TRPV6 were both shown to stim-
ulate NFAT-dependent gene transcription in prostate cancer cells [26,9,
27]. The use of various calcium channel blockers (against voltage-
activated and non-voltage-activated channels) has supported the idea
that calcium inﬂux plays a role in cell proliferation. Antiproliferative ef-
fects have been demonstrated in various tissues, in response to the
blockade of voltage-activated and non-voltage-activated channels.
This result was also conﬁrmed by knock-down of calcium channel ex-
pression,which strongly inhibited cell proliferation. These observations,
as well as variations in channel expression during the cell cycle, suggest
that a decrease in calcium channel expression will lead to cell cycle
arrest [28]. However, some cancers are characterized by alterations in
speciﬁc aspects of calcium signaling involved in the proliferative pheno-
type. For instance, enhanced TRPC3-dependent Ca2+ inﬂux leads to in-
creased proliferation in ovarian cancer [29]. Other studies have shown
the TRPC1 knock-down induced cell growth arrest by blocking the cellcycle in G0/G1 phase in endothelial progenitor cells [30] or by causing
incomplete cytokinesis in gliomas [31].
3.1. Calcium channels, proliferation and prostate cancer (Fig. 1)
Inmen, prostate cancer (PCa) is one of themost frequent and deadly
cancers. The progression of the disease is usually slow or mild in
diagnosed patients, but themetastatic form is the secondmost common
cause of mortality [32]. The early stages of this cancer are androgen-
dependent, unlike the late stage. Ablation is the ﬁrst-line treatment,
but some patients relapse because of the dissemination and survival
properties of the resistant cells. Pharmacological or surgical androgen
deprivation therapies are used for treatment of advanced PCa, but alter-
ations in Ca2+ homeostasis contribute to PCa cell resistance to androgen
deprivation. Alterations in calcium entry pathways through PM calcium
channels are also implicated in maintaining cancer cell proliferation.
Changes in expression of TRP channels have been implicated in PCa,
including TRPV1, TRPV2, TRPV6, TRPM8, TRPM2, and TRPC6. TRPV6
(TRP vanilloid subfamily) is a highly Ca2+-selective ion channel with a
preference for Ca2+ over monovalent cations. This property allows
TRPV6 to support selective Ca2+ inﬂux pathways in non-excitable
cells, and these channels have been reported to play a role in PCa. Tran-
scripts of TRPV6 are detectable in PCa, while the expression of TRPV6
mRNA is low or undetectable in benign human prostate tissue [33].
Expression of TRPV6 mRNA is also increased in human PCa cell lines
(LNCaP, PC-3) compared to normal and benign epithelial cells (PrEC,
BPH1) [34]. TRPV6 is considered to be a strong marker of tumor pro-
gression and subsequent invasion, since the expression of TRPV6
mRNA is high in advanced PCa, and signiﬁcantly correlates with the
Gleason N7 grading [35,33]. TRPV6 supports highly calcium-selective
currents in prostate cells [36–38]. Some data obtained in human PCa
cell lines (LNCaP) suggested that TRPV6 is constitutively open, and me-
diates calciumentry in these cellswithout speciﬁc activation [27]. TRPV6
overexpression in LNCaP cells enabled investigators to record a calcium-
sensing Ca2+ ITRPV6 current, which could be distinguished from native
ISOC by mechanism of activation, for instance [37]. However, in PCa
cells, TRPV6 was shown to contribute to SOCE in addition to TRPC1
and Orai channels, but TRPV6 was not transactivated by STIM1, as SOC
was [39]. It was suggested that the increased calcium entry in PCa
cells and the contribution of TRPV6 to SOCE involve translocation of
the TRPV6 channel to the plasma membrane via the Orai1/TRPC1-
mediated Ca2+/Annexin I/S100A11 pathway [39]. TRPV6 was shown
to decrease the proliferation rate, as well as cause accumulation of
cells in the S-phase of the cell cycle [27]. Treatments with siRNA-
TRPV6 also suggest that its role in cell proliferation is affected by
calcium-dependent NFAT transcription factor-mediated signaling path-
ways. Furthermore, such cell cycle markers as cyclin D1, CDK4, and
PCNA were detected in tumors induced by TRPV6-overexpressing PC3
cells [39].
Receptor-operated channels or second-messenger-operated chan-
nels are also very important mediators of calcium entry in response to
extracellular agonist and PLC-pathway activation. Members of the
TRPC subfamily are known to constitute ROCs and SMOCs, and TRPC6
protein andmRNA expressions were found to be signiﬁcantly increased
in prostate cancer tissues when compared to benign prostatic hyperpla-
sia (BPH) cases. TRPC6 expression was associated with histological
grade andGleason score increase, and extra-prostatic extension of pros-
tate cancer [40]. Similarly to TRPV6, TRPC6 was described as controlling
the proliferation andNFAT pathways. Alpha1-adrenergic receptors (AR)
were shown to promote the proliferation of primary human prostate
cancer epithelial (hPCE) cells by inducing TRPC6-dependent Ca2+
entry and subsequent activation of NFAT. TRPC6 silencing by antisense
decreased both hPCE cell proliferation and alpha1-AR-induced calcium
entry [26].
In response to these studies, the group of Natalia Prevarskaya has
proposed that basal prostate cancer cell proliferation is under the
Fig. 1. Implication of plasma membrane calcium channels in cell cycle regulation and proliferation in prostate cancer cell lines. TRPV6-dependent calcium entry and TRPC6-dependent
calcium entry in response to catecholamines regulate proliferation through a NFAT pathway. Cell cycle progression is also regulated through Cyclin E, which is known to be under the con-
trol of theNFAT pathway. Heteromeres of Orai1 andOrai3 (here postulated as a hexamer of twoOrai3 and fourOrai1 according to ref [46]) conduct an arachidonic acid-dependent calcium
entry. In this hypotheticmodel, this inﬂux regulates proliferation throughNFAT and ERKpathways and cell cycle progression through Cyclin D1, which is known to be under the control of
ERK pathway. ERK phosphorylation can be regulated by the calcium-dependent calmodulin–CAMK pathway. TRPM7was suggested to regulate proliferation under the control of choles-
terol and through AKT and ERK pathways. ERK phosphorylation can be regulated by the calcium-dependent calmodulin–CAMK pathway and the AKT–Raf–MEK pathway.
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volved in the mitogenic effect of catecholamines [9].
Among TRP channels, TRPM7 is distinctive in its own atypical serine/
threonine kinase domain, and in its permeability to Ca2+ and Mg2+.
TRPM7 is expressed in control and prostate cancer cells. It is of interest
that an increase in the extracellular Ca2+/Mg2+ ratio led to a signiﬁcant
increase in the cell proliferation of PCa cells when compared with
control cells [41]. TRPM7 expression was not dependent on the Ca2+/
Mg2+ ratio per se. However, the same group showed that cholesterol
treatment activates TRPM7 channels, thereby increasing cytosolic
Ca2+ levels. This not only enhances TRPM7 expression, but also pro-
motes cell proliferation in PCa cells [41]. Cholesterol increases Ca2+
entry via the TRPM7 channel, which promotes the proliferation of pros-
tate cells by inducing the activation of the AKT and/or the ERKpathways
[41]. This may be one of the cellular mechanisms explaining why high
circulating cholesterol levels have been shown to increase the risk of
overall aggressive PCa [42]. Among the melastatin subfamily, the
TRPM8 expression level was found to be elevated in androgen-
sensitive cancerous cells compared with normal cells [43,44]. Experi-
ments using LNCaP cells, the TRPM8 antagonist capsazepine, and
TRPM8 siRNA indicate that this channel is required for cell survival,
but no evidence of effects on cell proliferation has been provided [45].
A recent study has suggested a predominant role of Orai proteins in
LNCaP cells [46,46]. Silencing of Orai isoforms substantially reduced
LNCaP proliferation and mediated a downregulation of the oncogenic
cell-cycle protein cyclin D1, which is involved in G1 phase progression.
Silencing of STIM1 had no effect, suggesting a SOCE-independent
regulation. Conversely, PCa progression was associated with enhanced
Orai3 expression, which favors its heteromerization with Orai1 to
form a store-independent channel. Heteromeric association of Orai1/
Orai3 was thus proposed to control the proliferation of PCa cellsindependently of STIM1 and SOCE. These Orai1/Orai3 heteromeric
channels support arachidonic acid-mediated Ca2+ entry, thereby pro-
moting LNCaP cell proliferation.
Surprisingly, although PCa cells are not an electrically-stimulated
type of cell, expression of voltage-operated calcium channels has also
been suggested to be involved in the control of cell growth. The L-type
calcium channel CACNA1D gene expression levels were signiﬁcantly
higher in PCa tissues than in non-cancer tissues, and were highly
expressed in androgen-resistant PCa [47]. The study demonstrated
that decreasing CACNA1D gene expression suppressed androgen-
stimulated calcium inﬂux, androgen receptor transactivation, and cell
growth in PCa cells. A role for T-type Ca2+ channels in proliferation
has been also suggested in prostate tumors [48,49]. The small molecule
TH1177, which inhibits low-voltage activated T-type Ca2+ channels,
reduced PCa cell proliferation in vitro by a cytostatic mechanism.
However, TH1177 was shown to affect intracellular Ca2+ increase
after depletion of Ca2+ stores by thapsigargin or after ATP stimulation
[48]. Moreover, a small proportion of LNCaP cells displayed a weak in-
ward calcium current (LVA T-type properties), and this proportion
and the calcium current density are increased during neuroendocrine
differentiation [49]. T-type calcium channels participate in a “window”
calcium current active at restingmembrane potential, and it is proposed
that this voltage-dependent calcium channel could participate in the
stimulation of mitogenic factor secretion by neuroendocrine prostate
cells.
3.2. Calcium channels, proliferation and breast cancer (Fig. 2)
Breast cancer is the most frequent cause of death from cancer in
women, worldwide. The most common form is invasive ductal carcino-
ma, and the aggressiveness of the different cancers has been correlated
Fig. 2. Implication of plasma membrane calcium channels in cell cycle regulation and proliferation in breast cancer cell lines. Orai1 channels (here represented as the canonical
homotetramer) conduct a constitutive calcium entry under the control of SPCA2 membrane proteins. This inﬂux regulates proliferation through ERK pathway and cell cycle progression
through Cyclin D1, which is known to be under the control of ERK pathway. ERK phosphorylation can be regulated by the calcium-dependent calmodulin–CAMK pathway. MCF7 cell pro-
liferation can be regulated through this pathway by a calcium entry dependent on TRPC6/TRPC1 tetrameric channels and stimulated by a Calcium-sensing Receptor. In MDA-MB-231
breast cancer cell lines, heteromeric TRPC6-TRPC3 channels were suggested to regulate proliferation through calcium entry. TRPM7 and TRPV6-dependent calcium entry were also sug-
gested to regulate the proliferation of breast cancer cells.
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pressionwill allow treatmentwith hormonal therapy, and this is usually
associated with a good prognosis. The remodeling of calcium signaling
appears to differ between subtypes of breast cancer and can be mediat-
ed via variousmechanisms leading to different consequences (ref. [50]).
TRPC1, TRPC3, TRPC6, TRPM7, TRPM8, and TRPV6 expressionswere cor-
relatedwith breast cancer progression (ref. [51]). As for prostate cancer,
various TRP channels, such as TRPV6, TRPC6 and TRPM7, have been im-
plicated in the control of breast cancer cell proliferation.
TRPV6 expression is increased in tumors of the breast and also of the
prostate, thyroid, colon and ovary [52,53]. High levels of TRPV6were re-
ported in a subset of breast cancer biopsies [54,55], which likely belong
to the estrogen receptor-negative group [56]. TRPV6 silencing was
shown to reduce basal calcium inﬂux and cellular proliferation in T-
47D cells, a breast cancer cell linewith increased endogenous TRPV6 ex-
pression [56]. The percentage of cells in S-phase signiﬁcantly decreased
with TRPV6 knockdown, and TRPV6 silencing caused cells to accumu-
late in the G1-phase at 24 h. This accumulation in the G1-phase is likely
due to the reduction of Ca2+ inﬂux, since Ca2+ is well-known to pro-
mote the G1-phase to S-transition. It is of interest that it has been
shown that the tumor suppressor Numb1 interacts with TRPV6, and
the resulting complex inhibits TRPV6-dependent calcium entry [57]. In
this study, it was suggested that GSK3β, MAP Kinase, and AKT are intra-
cellular signaling pathways involved in the TRPV6-mediated cell prolif-
eration of TRPV6-overexpressing MCF-7 and PC-3 breast cancer cells.
The downstream signaling pathway appears to be different from the
one proposed in PCa cells.
Different studies have reported signiﬁcantly-elevated TRPC6 mRNA
in breast tumor samples compared with control samples [55,58].
TRPC3 and TRPC6 were found to be in an immunoprecipitable complex.
Hyperforin, a speciﬁc activator of TRPC6, signiﬁcantly decreased the
growth and viability of the breast cancer cell lines, but had no effect
on the non-cancerous breast cell line. Silencing of TRPC6 resulted in a
signiﬁcant reduction in cell growth. TRPC6 siRNA reduced the growth
of MDA-MB-231 breast cancer cells but not their viability [58]. These
data suggest that TRPC3 and TRPC6 form heteromultimeric channels
in the breast cancer epithelial cell line MDA-MB-231, which can beactivated in response to agonist-stimulated PIP2 hydrolysis and regulate
cell proliferation. Similarly, a cationic channel in MCF-7 cells was pro-
posed to be constituted as heteromultimers, including both TRPC6 and
TRPC1 [59]. It was proposed in this study that the Calcium-sensing
Receptor (CaR) activated ERK1/2 via a PLC/PKC-dependent pathway
[60] TRPC1 was suggested to be required for the ERK1/2 phosphoryla-
tion, fo Ca2+ entry and for the CaR-proliferative effect in MCF-7
cells [60]. As for TRPC6, high levels of TRPC1 expression were reported
in human breast ductal adenocarcinoma (hBDA) tissue, in comparison
to adjacent non-tumor tissue [55]. This correlated with the Scarff-
Bloom-Richardson (SBR) grade, Ki67 proliferation index, and tumor
size.
Among the TRPmelastatin subfamily, TRPM7 levels in human breast
cancers indicate that TRPM7 overexpression may be a feature of higher
grade and highly proliferative breast cancers [61]. It was proposed that
TRPM7may play a role in the proliferation of MCF-7 breast cancer cells.
Moreover, a study reported that TRPM7 and TRPM8 expressions strong-
ly correlated with various tumor aggressiveness markers [55].
Numerous studies have suggested a role of either the calcium Orai
channels or the endoplasmic reticulum Ca2+ level sensor STIM1 pro-
teins in breast cancer progression (ref. [50]). Orai1 mRNA levels were
shown to be elevated in various breast cancer cell lines, such as T-47D,
MCF-7 and MDA-MB-468, compared with the non-breast cancer-
derived cell lines 184A1 and 184B5. Orai1 up-regulation was shown to
be an indicator of the poor-prognosis basal breast cancer subtype, as
were higher mRNA levels of STIM1 and lower levels of its related iso-
form STIM2. Orai1 and STIM1 upregulation suggested that a remodeling
of SOCE may be a signature of breast cancers with greater aggressive-
ness and metastasis [62]. However, a study revealed a mechanism for
the activation of Orai1 by SPCA2 that is independent of ER and Golgi
Ca2+ stores and sensors [63]. This store-independent mode of endoge-
nous Orai1 activation in breast cancer-derived MCF-7 cells underlies
constitutive Ca2+ signaling, which regulates cell-cycle progression and
proliferation. This regulation is mediated by the RAS–ERK pathway.
SPCA2 and Orai1-mediated increase of calcium entry was suggested to
promote a constitutive activation of RAS signaling, monitored by ERK
activation and expression of the downstream protein cyclin D1 [63].
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Lung cancer is the most common and malignant cancer in men, and
the second-most in women. The predominant type is non-small cell
lung cancer (NSCLC) representing 70–80% of lung cancer, followed by
small cell lung cancer (SCLC).
Recent studies have implicated TRPC1, TRPC3, TRPC4, TRPC6,
TRPM7, and TRPM8 as playing a role in lung cancer. Among the TRPC
subfamily, the expression of TRPC1, TRPC3, TRPC4, and TRPC6 was cor-
related with differentiation grades in NSCLC [64]. The same study re-
ported that the inhibition of TRPC channels decreased cell mitosis, by
using the pore-blocking antibodies T1E3 and T367E3 to inhibit speciﬁ-
cally TRPC1 and TRPC3/6 in A549 cells. Blocking of TRPC channels
inhibited A549 cell proliferation, while overexpression of TRPC1 and
TRPC6 (but not TRPC3 and TPC4) increased proliferation. Another
study conﬁrmed that TRPC1 is implicated in the cell proliferation of
NSCLC cell lines [65]. Knock-down of TRPC1 with siRNA inhibited cell
proliferation and induced G0/G1 cell cycle arrest, resulting in a dramatic
decrease in cell growth. TRPC1was suggested to be themediator of this
regulation through epidermal growth factor receptor (EGFR) phosphor-
ylation and the activation of EGF-induced PI3K/AKT and MAPK down-
stream signaling pathways [65]. This study proposed that Ca2+ entry
through TRPC1 constitutes an ampliﬁcation loop of EGF-dependent
cell proliferation: TRPC1-dependent Ca2+ entry is triggered by EGFR
stimulation, and conversely, it enhances EGFR autophosphorylation
and activity. The effect of TRPC1 could be mediated by SOCE, since
TRPC1 silencing signiﬁcantly reduced thapsigargin-induced SOCE in A-
549 cells.
A recent study reported that Orai3 also constituted a native SOCE
pathway inNSCLC, which controlled cell proliferation and cell cycle pro-
gression, likely via the AKT pathway [66]. Orai3 was overexpressed in
cancer tissues as compared to non-tumorous tissues, and Orai3 staining
wasmore intense in high-grade tumors. SilencingOrai3 signiﬁcantly re-
duced SOCE, inhibited cell proliferation and arrested cells of two NSCLC
cell lines in G0/G1 phase. These effects were concomitant with a down-
regulation of cyclin D1, cyclin E, CDK4 and CDK2 expressions. Moreover,
Orai3 silencing decreased AKT phosphorylation levels. In contrast, over-
expression of Orai1 in A-549 cells resulted in the inhibition of EGF-
mediated cell proliferation, as well as in attenuation of EGF-mediated
store-operated calcium inﬂux [67]. Flow cytometry revealed that the
overexpression of Orai1 resulted in G0/G1 cell cycle arrest.
These various studies suggest that SOCE is implicated in the prolifer-
ation of lung cancer cell lines, but it is not clear how or by what chan-
nels. It has been demonstrated recently that Orai3 is a part of a native
store-operated Ca2+ entry in estrogen receptor-positive breast cancer
cells [68], whereas Orai1 has been described since 2006 as an essential
component of the store-operated calcium channels [69]. TRPC1 is also
involved in SOCE of lung cancer cell lines [65], and it is proposed by an-
other study that local Ca2+ entry via Orai1 regulates plasmamembrane
recruitment of TRPC1 in HSG cells where Orai1, TRPC1 and STIM1 SOCE
are found [70]. However, Orai3 can form store-independent Ca2+ chan-
nels [71] and heteromeric association of Orai1/Orai3 was proposed to
control the proliferation of prostate cancer cells independently of
STIM1 and SOCE.
4. Cell migration and metastasis
Cell migration is a process whereby cancerous cells exit the primary
tumor, and then disseminate and invade other tissues to developmetas-
tases. In solid cancers, the majority of cells adopt a mesenchymal mode
of motility. Recent studies have emphasized the role of certain voltage-
independent Ca2+ channels, especially subtypes from the Orai and the
Transient Receptor Potential (TRP) families, in the process ofmesenchy-
mal migration and metastasis formation. Metastasis involves many
Ca2+-dependent processes, including cell deformation, invasion,migra-
tion and adhesion.Calciumhas been shown to be involved in various steps ofmigration,
including cytoskeleton and focal adhesion (FA) organization, traction
force, and directional sensing. The transient increase of this ubiquitous
intracellular second messenger triggers speciﬁc cellular responses
according to its spatial and temporal distribution. A global increase in
intracellular calcium concentration usually plays a role in rear detach-
ment by a transient front-to-rear calcium gradient. It involves TRP,
voltage-gated calcium channels and the PLC/IP3R pathway. Transient
and local microdomains of calcium have been visualized in different
areas of themigrating cells. For example, the so-called “calciumﬂickers”
were restricted at lamellipodia and their occurrence was dependent on
the stretch-activated channel TRPM7 [72]. This local increase of calcium
does not propagate as a wave through the cell, but its amplitude in-
creases by the local release of IP3 receptor. This signal plays a role in
the organization of FA and actin cytoskeleton by acting on calcium-
dependent proteins such as calpain or calmodulin kinase II (caMKII).
These, in turn, activate effectors and signaling pathways, such asmyosin
light chain kinase (MLCK), focal adhesion kinase (FAK), PI3K, and pyk2.
It is suggested that TRPM7-induced calcium entry is responsible for the
FA disassembling and for the reduction of cell adhesion that promote
cell migration. The “calcium ﬂickers” have been also involved in the di-
rectionality of chemoattractant-dependent migration. Without such
ﬂickering, cells move faster but they decrease their ability to respond
to directional cues [72,73].
4.1. Calcium channels, migration and metastasis in prostate cancer (Fig. 3)
The TRPV2 channel is activated in most non-excitable cells by
various growth factors or hormone receptors, which promote TRPV2
dynamic translocation from the endosomal compartment to the PM
through a phosphatidylinositol-3 kinase (PI3K)-dependent pathway.
TRPV2 expression was reported to be higher in samples from patients
with metastatic disease than in samples derived from solid primary tu-
mors, which is consistent with a role in tumor cell migration/invasion.
In aggressive, castration-resistant cancer, Monet et al. described a high
expression level of the activated channel TRPV2 in the metastasis, com-
pared to primary tumor [74]. This observation suggested a role of TRPV2
in migration and invasion. In this study, different in vitro experimental
conditions were used to mimic androgen ablation therapy in men,
which highlighted an androgen-dependent expression of TRPV2: An-
drogen deprivation induced the expression of TRPV2, as well as an in-
crease in basal cytosolic calcium and an augmentation of migration.
Moreover, the inhibition of TRPV2 decreased the size of the tumor and
the expression of many invasion markers. This work suggested that in
the castration-resistant stage, de novo TRPV2 induces a constitutive cal-
cium increase which plays a role in the motility of metastatic cells. This
supports the idea that TRPV2 could be a target of androgen-independent
aggressive PCa [74]. TRPV2 has also been implicated in the migration
of PCa cells, independently of androgen. Indeed, lysophospholipids,
lysophosphatidylcholine (LPC) and lysophosphatidylinositol (LPI) can
activate the PI3K pathway, which induces the PM translocation of
TRPV2 and in turn promotes cell migration of PC3 cells [75]. The same
physiological effect of TRPV2 has been described in adrenomedullin
(AM) activation. Adrenomedullin is a multifactorial regulatory protein
involved in different cancerogenesis processes. AMwas shown to induce
PI3K activation, TRPV2 translocation to the PM, and an increase in cyto-
solic calcium concentration, which are suggested to promote themigra-
tion/invasion of PC3 cells through FAK phosphorylation [76].
It has been suggested that TRPM7 regulates the mobility of PCa cells
via cholesterol-dependent calcium entry. High circulating cholesterol
levels have been shown to increase the risk of overall aggressive PCa.
Cholesterol activates the TRPM7 channel, which increases the basal cal-
cium concentration and stimulates the calcium dependent protein,
calpain. Calpain decreases E-Cadherin expression, which may be the
link between TRPM7 andmigration [41]. TRPM8 is a cold-sensing chan-
nel, responding to changes of temperature or the presence ofmenthol. It
Fig. 3. Plasmamembrane channels involved in the intracellular calcium increase link tomigration in prostate cancer cells. A large panel of stimuli can activate directly or indirectly speciﬁc
TRP members (TRPC, TRPV and TRPM). The TRP induced cytosolic calcium increase has various targets that lead to a loose or a decrease of adherence and so a raise in cell mobility. Cho-
lesterol can activate the stretch activated channel TRPM7 that induces the stimulation of the calcium dependent protein: calpain. Calpain dependent proteolysis is involved in E-Cadherin
degradation. TRPV2 activation needs the translocation of the channel for submembrane vesicles to the plasma membrane. For the purpose, different stimuli act via G protein associated
receptor. The intracellular calcium increase is associatedwith phosphorylation by FAK inducing FA destabilization. TRPM8 is the only plasmamembrane calcium channel link to a protec-
tive effect of prostate cancer cells by reducing cell mobility. TRPM8 associated calcium increase inhibits FAK phosphorylation and so plays a role in the maintaining of FA that limits cell
migration. Lysophosphatidylcholine (LPC) and lysophosphatidylinositol (LPI), adrenomedullin (AM), focal adhesion kinase (FAK), focal adhesion (FA), prostate speciﬁc antigen (PSA).
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a ROC: PSAprostate speciﬁc antigen via bradykinin receptor 2. It induces
the accumulation of TRPM8 at PM, and the process reduces cell
migration though the decrease of FAK phosphorylation. TRPM8 is the
only TRP channel described to have a protective role in prostate cancer
[77,78].
A recent study involved SOCE and migration of prostate cancer cells
through bisphenol A (BPA) incubation. BPA is an endocrine-disrupting
compound. It is the principal constituent of reusable water bottles,
metal cans and plastic food containers. BPAwas found in 95% of samples
of adult urine. It is thought to be related to many cancers. BPA regulates
the expression of an important component of SOCE: Orai1 (but not
STIM1), and also other channels, such as TRPV6 and Ca2+-activated po-
tassium channels BKca and IKca in LNCaP cells. The inhibition of SOCE
reduces the migration of androgen-dependent or -independent pros-
tate cells [79].
Taken altogether, Orai and TRP calcium channels are involved in the
regulation of the migration of PCA cells. The expression or overexpres-
sion of these channels is linked to an increase of mobility (except for
TRPM8 in prostate cancer), and can regulate the metastatic stage of
carcinogenesis. TRP andOrai channelsmay bepromising targets for can-
cer therapy, and modulating pathways by blocking PM Ca2+ channels
presents a promising therapeutic potential to prevent the spread of
PCa cells.
4.2. Calcium channels, migration and metastasis in breast cancer (Fig. 4)
Breast cancer-related mortality is associated with the development
of metastatic potential of the primary tumor. Recent studies have em-
phasized that PM calcium channels are critical for breast tumor cell mi-
gration, invasion, and metastasis dissemination. The remodeling of theCa2+-toolkit appears to differ among subtypes of breast cancer, but gen-
erally involves Orai and TRP channels, as was previously noted for pros-
tate cancer. Voltage-gated channels have not yet been implicated
directly in migration in breast cancer. However, Palmieri et al. propose
an epigenetic regulation of CACNA2D3 mRNA: The methylation of
CACNA2D3 CpG island may contribute to the metastatic phenotype of
breast cancer [80].
Although the expression of SOC, and in particular, of some TRP, was
previously correlated to the aggressiveness of breast cancer [55,58], the
main SOCE actors Orai1 and STIM1 were recently shown to be directly
involved in the migration and invasion of the human invasive cell line
MDA-MB-23 [77]. It was reported that knock-down of Orai1-STIM1 by
siRNA or inhibition by pharmacological treatment decreased themigra-
tion and the invasion in vitro (by Boyden assays) and in vivo (xenograft
in mice). Orai1 and STIM1 expressions were directly related to the mi-
gration ability of breast cancer cells, because the overexpression of
both proteins in non-tumorigenous mammary cells (MCF-10a) with
low endogenous Orai1/STIM1 expression did enhance cell migration
[77]. This effect was suggested to be linked to the SOCE-dependent in-
tracellular calcium increase, which induced a defect in the turnover of
FA. Indeed, the inhibition of Orai1/STIM1 led to an increase of larger
FA in the peripheral part of the cell, and this effect was dependent of
Ras and Rac pathways [77]. These data are consistent with the role of
STIM1- and Orai1-dependent SOCE in the aggressiveness of breast can-
cer and development of metastasis.
However, Orai1 has also been suggested to be involved in tumori-
genesis in a STIM1- and SOCE-independent manner [63]. The analysis
of calcium entry in MCF-7 breast cancer cells demonstrated that Orai1
was constitutively activated by the Ca2+-ATPase SPCA2a. In contrast
to its well-known Golgi function, SPCA2 co-localized at PM with Orai1.
The SPCA2a–Orai1 interaction mediated the activation of the calcium
Fig. 4. Plasmamembrane channels involved in the intracellular calcium increase link to migration in breast cancer cells. In breast cancer cells, TRPC and Orai family are themain actors of
intracellular calcium increase involved inmigration or invasion. These channels could be activated by calcium depletion or receptor/PLC pathway leading respectively to SOCE or ROCE but
could also be activated bymore original pathways. Indeed, like already described, TRPC3 is stimulated by ROCE associated PKC/IP3 pathways and the ER calcium sensor STIM1 activates the
plasmamembrane channel: Orai1 andmore recently described Orai3 (we have arbitrarily chosen to represent Orai3 as homotetramers like Orai1-based SOC because there is no informa-
tion about its stoichiometry for its SOC activity). In the other hand, Orai1 mediates also a constitutive cytosolic calcium increase link to K+ channel membrane depolarization or by the
Ca2+-ATPase SPCA2a activation. The entries are independent of intracellular calcium store or of ATPase activity of SPCA2a. Moreover Orai3 is known to be PLA2/acid arachidonic activated
channel (ARC) but in breast cancer cells Orai3 can be activated by STIM1 as Orai1 to promote SOCE. All the processes lead to cytosolic calcium increase that stimulates different effectors:
calpain or Focal adhesion (FA) proteins. The FA disassembling and defect of turnover promote migration and/or invasion in breast cancer cells. Polyunsaturated fatty acids (PUFAs).
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Moreover, Feng et al. showed the tumorigenic implication of SPCA2a
and Orai1 in breast cancer by in vitro (soft agar colony assays) or
in vivo (subcutaneous injection of MCF7 cells) experiments.
Orai3 iswell-described as a PLA2/arachidonic acid-activated channel
(ARC) but it is also implicated in the regulation of breast cancer in a
STIM1-dependent manner. Indeed, Orai3 and STIM1 were suggested
to form the main SOCE-induced complex in estrogen-positive MCF7
cells, unlike the coupled Orai1-STIM1 in estrogen-negative cells [68].
In MCF-7, Orai3-dependent SOCE induced the phosphorylation of
calcium-dependent effectors ERK and FAK; and knock-down of Orai3
reduced the invasive power of MCF-7 in Boyden and soft agar colony
assays.Moreover, in vivo orthotopic injection of shOrai3MCF-7 cells de-
creased mammary tumor development in mice [81].
SOCE can also be potentiated by an increase of the driving force of
calcium across the plasma membrane. Two K+ channels, hEag1 and
Sk3, were shown to play a role in the migration of breast cancer cells,
and hyperpolarization of the membrane due to the activation of hEag1
or Sk3 was suggested to potentiate Orai1-dependent calcium entry
and to promote migration [82,83]. Sk3 action was proven to bemediat-
ed through an association with Orai1, and the Sk3–Orai1 complex was
demonstrated to regulate a constitutive Ca2+ entry, calpain activation
and cell migration [83].
The stretch-activated channel TRPM7 is a Ca2+/Mg2+-permeable
channel, which is necessary for generating “calcium ﬂickers” in
lamellipodia ofmigrating cells [73]. TRPM7 is also involved inmigration
andmetastasis development in breast cancer cells, but this role is due to
its kinase activity (MAPK pathway activation and regulation of cells ad-
hesion) in a calcium-independent fashion [84,85].Other TRP family members can also regulate the migration of breast
cancer cells. For instance, TRPV6 was found to be more highly-
expressed in invasive parts of tumors, and this observationwas correlat-
ed in vitro with a TRPV6 role in migration and invasion [55]. Moreover,
the activity of TRPC3 has been suggested to be regulated by polyunsat-
urated fatty acids (PUFAs). This ﬁnding could be a new approach to reg-
ulate calcium inﬂux in breast cancer cells [86]. Exogenous PUFA
inhibited TRPC3-dependent calcium entry evoked by thapsigargin. The
migration of MCF-7 cells was reduced by 2-APB, a non-speciﬁc SOCE in-
hibitor [83], but this effect could also be due to the inhibition by 2-APB
of store-operated Orai channels.
In breast tumors, the intracellular calcium increase by activation or
overexpression of PM channels is associated with an increase in themi-
gration and invasion properties of cancer cells. Recent studies show that
Orai/STIM-dependent SOCE is involved in such migration and invasion
of breast cancer cells, as is Orai1-dependent constitutive calcium
entry, when associated with Sk3 Kca channels. These data suggest that
STIM and/or Orai might be good pharmacological targets for metastasis
inhibition.
4.3. Calcium channels, migration and lung cancer
Lung cancer has the property of developing earlymetastasis, and the
survival rate is quite low [32]. Invasion, metastasis, and recurrence are
common biological characteristics of lung cancer, and they are also the
major obstacles hampering therapeutic interventions leading to im-
proved prognosis. Although calcium channels are strongly involved in
the proliferation of lung cancer, there is very little data concerning
these channels and cell migration. One interesting study suggests a
2520 N. Déliot, B. Constantin / Biochimica et Biophysica Acta 1848 (2015) 2512–2522role for TRPM7 in this pathology. In the NSCLC, TRPM7 is expressed in
lung carcinoma tissues.Moreover, mRNA and protein levels are regulat-
ed by EGF, an activator of migration in this lung cancer model. The role
of TRPM7 in migration was evaluated by siRNA knockdown or by non-
speciﬁc pharmacological inhibition. As has already been described for
breast cancer, the inhibition of TRPM7 induced a decrease of cell migra-
tion in basal or EGF-activated conditions [87].5. Concluding remarks
The study of the role of calcium channels in molecular mechanisms
of cancer transformation is still a novel area of research. These studies,
while mostly conducted in cancer cell lines, nonetheless support the
idea that a diversity of plasma membrane channels participates in the
remodeling of Ca2+ homeostasis. This then regulates various hallmarks
of cancermalignancy, such as uncontrolledmultiplication and increased
migration and invasion capacity. However, little is yet understood,
concerning the intracellular signaling cascadesmobilized by calcium in-
ﬂux that participate in cancer cell behavior. The intent of the current re-
view is to bring together some of the calcium channel-dependent
pathways described in prostate, breast and lung cancers. In these cancer
cell types, the calcium channels involved in calcium signaling pathways
that promote tumor activity are primarily non-voltage-activated calci-
um channels; they belong to the TRP superfamily (TRPC, TPRPV and
TRPM families) and the Orai family. TRP and Orai channels are part of
many signaling cascades, and TRPV can sense changes in the physical
and chemical environments of cancer cells. However, the mechanisms
triggering the activation of these channels in cancer cells are poorly un-
derstood, depending in some cases upon the stimulation of transmem-
brane receptors by extracellular ligands from the tumor environment.
Some experimental data also suggests that plasma membrane non-
voltage-activated calciumchannels, such as TRPV6,may be constitutive-
ly active in cancer cells. This indicates that these channels are open
without the presence of a determined stimulus in the experimental con-
ditions, in the so-called “resting cells”. How, exactly, such non-voltage-
activated calcium channels could be open during “resting” conditions in
cancer cells is not understood, but may involve macromolecular signal-
ing complexes: Channels and enzymesmay cooperate to generate a cal-
cium inﬂux at resting conditions. In breast cancer cells, the cooperation
between the Sk3 channel hyperpolarizing the PM and Orai1 channels
was proposed to promote a constitutive calcium entry [75]. Other con-
ditions favoring the open conﬁguration may involve phosphorylation
of channels by associated kinases or other kinds of post-transductional
channel modiﬁcation by oncogene-activated pathways.
A number of various calcium channels, aswell as calciumpumps and
transporters, have been linked with cancer cell behaviors and patho-
physiological cancer hallmarks. Changes in activation and/or expression
of calcium-transporting proteins lead to alteration of the global calcium
homeostasis, but also may cause modiﬁcations in subcellular calcium
microdomains and localized calcium signals. These can affect calcium-
dependent signaling processes relevant to tumorigenesis. The studies
cited above suggest that an increase in PM calcium channel expression
and/or activity can sustain elevated calcium entry (constitutive or
under the control of extracellular signals), thus promoting increased
cell proliferation and migration. Most of these channels are not speciﬁc
to cancer cells and are expressed in numerous normal tissues, but some
are speciﬁcally more active or are overexpressed in cancer cells. A vari-
ety of non-voltage-operated calcium channels are changed in the same
cancer type. According to the literature, it is likely that several types of
channels can contribute to and cooperate in the same tumorigenic cel-
lular process, or can be involved in a different sequence of events during
tumorigenesis. However, since these various studies do not support the
idea that one channel can be conclusively related to a particular type of
cancer, it remains to be determined whether there are speciﬁc associa-
tions of channels that can be identiﬁed.Targeting these non-voltage-operated channels with pharmacologi-
cal antagonists could be of interest to regulate uncontrolled tumor cell
proliferation, migration, and invasion. In some cancer cells, reduced cal-
cium entry confers resistance to apoptosis by preventing sustained cal-
cium increase in response to pro-apoptotic stimuli [88]. One can also
speculate about the use of agonists of non-voltage-operated calcium
channels in order to promote in cancer cells a major calcium inﬂux
and a sustained elevation of [Ca2+]i. This could lead to the activation
of mitochondrial and cytosolic apoptotic pathways [89]. However,
selective pharmacological tools against most of these channels remain
to be discovered and developed. Since most of these channels are
expressed in healthy tissues, a goal would be to couple these chemical
agents to a targeting moiety, which will produce an active effector
only within the tumor environment.
Transparency document
The Transparency document associated with this article can be
found, in the online version.
References
[1] D. Hanahan, R.A. Weinberg, The hallmarks of cancer, Cell 100 (2000) 57–70.
[2] R. Sever, J.S. Brugge, Signal transduction in cancer, Cold Spring Harb. Perspect. Med.
5 (2015).
[3] M.J. Berridge, M.D. Bootman, H.L. Roderick, Calcium signalling: dynamics, homeosta-
sis and remodelling, Nat. Rev. Mol. Cell Biol. 4 (2003) 517–529.
[4] G.R. Monteith, D. McAndrew, H.M. Faddy, S.J. Roberts-Thomson, Calcium and can-
cer: targeting Ca2+ transport, Nat. Rev. Cancer 7 (2007) 519–530.
[5] H.L. Roderick, S.J. Cook, Ca2+ signalling checkpoints in cancer: remodelling Ca2+ for
cancer cell proliferation and survival, Nat. Rev. Cancer 8 (2008) 361–375.
[6] J.M. Lee, F.M. Davis, S.J. Roberts-Thomson, G.R. Monteith, Ion channels and trans-
porters in cancer. 4. Remodeling of Ca(2+) signaling in tumorigenesis: role of
Ca(2+) transport, Am. J. Physiol. Cell Physiol. 301 (2011) C969–C976.
[7] N. Prevarskaya, R. Skryma, Y. Shuba, Targeting Ca(2)(+) transport in cancer: close
reality or long perspective? Expert Opin. Ther. Targets 17 (2013) 225–241.
[8] J.L. Fiske, V.P. Fomin, M.L. Brown, R.L. Duncan, R.A. Sikes, Voltage-sensitive ion chan-
nels and cancer, Cancer Metastasis Rev. 25 (2006) 493–500.
[9] N. Prevarskaya, R. Skryma, Y. Shuba, Ion channels and the hallmarks of cancer,
Trends Mol. Med. 16 (2010) 107–121.
[10] N. Nielsen, O. Lindemann, A. Schwab, TRP channels and STIM/ORAI proteins: sensors
and effectors of cancer and stroma cell migration, Br. J. Pharmacol. 171 (2014)
5524–5540.
[11] K. Venkatachalam, C. Montell, TRP channels, Annu. Rev. Biochem. 76 (2007)
387–417.
[12] B. Nilius, G. Owsianik, The transient receptor potential family of ion channels,
Genome Biol. 12 (2011) 218.
[13] I.S. Ambudkar, H.L. Ong, Organization and function of TRPC channelosomes, Pﬂugers
Arch. 455 (2007) 187–200.
[14] M.D. Cahalan, STIMulating store-operated Ca(2+) entry, Nat. Cell Biol. 11 (2009)
669–677.
[15] P.F. Worley, W. Zeng, G.N. Huang, J.P. Yuan, J.Y. Kim, M.G. Lee, S. Muallem, TRPC
channels as STIM1-regulated store-operated channels, Cell Calcium 42 (2007)
205–211.
[16] K.T. Cheng, H.L. Ong, X. Liu, I.S. Ambudkar, Contribution of TRPC1 and Orai1 to
Ca(2+) entry activated by store depletion, Adv. Exp. Med. Biol. 704 (2011)
435–449.
[17] K. Vermeulen, D.R. Van Bockstaele, Z.N. Berneman, The cell cycle: a review of regu-
lation, deregulation and therapeutic targets in cancer, Cell Prolif. 36 (2003)
131–149.
[18] C.R. Kahl, A.R. Means, Regulation of cell cycle progression by calcium/calmodulin-
dependent pathways, Endocr. Rev. 24 (2003) 719–736.
[19] T. Capiod, Cell proliferation, calcium inﬂux and calcium channels, Biochimie 93
(2011) 2075–2079.
[20] L. Santella, The role of calcium in the cell cycle: facts and hypotheses, Biochem.
Biophys. Res. Commun. 244 (1998) 317–324.
[21] J.G. Chafouleas, L. Lagace, W.E. Bolton, A.E. Boyd III, A.R. Means, Changes in calmod-
ulin and its mRNA accompany reentry of quiescent (G0) cells into the cell cycle, Cell
36 (1984) 73–81.
[22] C.D. Rasmussen, A.R. Means, Calmodulin, cell growth and gene expression, Trends
Neurosci. 12 (1989) 433–438.
[23] N. Takuwa, W. Zhou, M. Kumada, Y. Takuwa, Ca(2+)-dependent stimulation of ret-
inoblastoma gene product phosphorylation and p34cdc2 kinase activation in
serum-stimulated human ﬁbroblasts, J. Biol. Chem. 268 (1993) 138–145.
[24] M. Tomono, K. Toyoshima, M. Ito, H. Amano, Z. Kiss, Inhibitors of calcineurin block
expression of cyclins A and E induced by ﬁbroblast growth factor in Swiss 3T3 ﬁbro-
blasts, Arch. Biochem. Biophys. 353 (1998) 374–378.
[25] M. Buchholz, A. Schatz, M. Wagner, P. Michl, T. Linhart, G. Adler, T.M. Gress, V.
Ellenrieder, Overexpression of c-myc in pancreatic cancer caused by ectopic
2521N. Déliot, B. Constantin / Biochimica et Biophysica Acta 1848 (2015) 2512–2522activation of NFATc1 and the Ca2+/calcineurin signaling pathway, EMBO J. 25
(2006) 3714–3724.
[26] S. Thebault, M. Flourakis, K. Vanoverberghe, F. Vandermoere, M. Roudbaraki, V.
Lehen'kyi, C. Slomianny, B. Beck, P. Mariot, J.L. Bonnal, B. Mauroy, Y. Shuba, T.
Capiod, R. Skryma, N. Prevarskaya, Differential role of transient receptor potential
channels in Ca2+ entry and proliferation of prostate cancer epithelial cells, Cancer
Res. 66 (2006) 2038–2047.
[27] V. Lehen'kyi, M. Flourakis, R. Skryma, N. Prevarskaya, TRPV6 channel controls pros-
tate cancer cell proliferation via Ca(2+)/NFAT-dependent pathways, Oncogene 26
(2007) 7380–7385.
[28] A.S. Borowiec, G. Bidaux, N. Pigat, V. Gofﬁn, S. Bernichtein, T. Capiod, Calcium chan-
nels, external calcium concentration and cell proliferation, Eur. J. Pharmacol. 739
(2014) 19–25.
[29] S.L. Yang, Q. Cao, K.C. Zhou, Y.J. Feng, Y.Z.Wang, Transient receptor potential channel
C3 contributes to the progression of human ovarian cancer, Oncogene 28 (2009)
1320–1328.
[30] C.Y. Kuang, Y. Yu, K.Wang, D.H. Qian,M.Y. Den, L. Huang, Knockdown of transient re-
ceptor potential canonical-1 reduces the proliferation and migration of endothelial
progenitor cells, Stem Cells Dev. 21 (2012) 487–496.
[31] V.C. Bomben, H. Sontheimer, Disruption of transient receptor potential canonical
channel 1 causes incomplete cytokinesis and slows the growth of humanmalignant
gliomas, Glia 58 (2010) 1145–1156.
[32] A. Jemal, F. Bray, M.M. Center, J. Ferlay, E. Ward, D. Forman, Global cancer statistics,
CA Cancer J. Clin. 61 (2011) 69–90.
[33] U. Wissenbach, B. Niemeyer, N. Himmerkus, T. Fixemer, H. Bonkhoff, V. Flockerzi,
TRPV6 and prostate cancer: cancer growth beyond the prostate correlates with in-
creased TRPV6 Ca2+ channel expression, Biochem. Biophys. Res. Commun. 322
(2004) 1359–1363.
[34] J.B. Peng, L. Zhuang, U.V. Berger, R.M. Adam, B.J. Williams, E.M. Brown, M.A. Hediger,
M.R. Freeman, CaT1 expression correlates with tumor grade in prostate cancer,
Biochem. Biophys. Res. Commun. 282 (2001) 729–734.
[35] T. Fixemer, U. Wissenbach, V. Flockerzi, H. Bonkhoff, Expression of the Ca2+-
selective cation channel TRPV6 in human prostate cancer: a novel prognostic mark-
er for tumor progression, Oncogene 22 (2003) 7858–7861.
[36] R. Schindl, H. Kahr, I. Graz, K. Groschner, C. Romanin, Store depletion-activated
CaT1 currents in rat basophilic leukemia mast cells are inhibited by 2-
aminoethoxydiphenyl borate. Evidence for a regulatory component that controls
activation of both CaT1 and CRAC (Ca(2+) release-activatedCa(2+) channel) chan-
nels, J. Biol. Chem. 277 (2002) 26950–26958.
[37] M. Bodding, V. Flockerzi, Ca2+ dependence of the Ca2+-selective TRPV6 channel, J.
Biol. Chem. 279 (2004) 36546–36552.
[38] A.F. Vanden, L. Lemonnier, S. Thebault, G. Lepage, J.B. Parys, Y. Shuba, R. Skryma, N.
Prevarskaya, Two types of store-operated Ca2+ channels with different activation
modes and molecular origin in LNCaP human prostate cancer epithelial cells, J.
Biol. Chem. 279 (2004) 30326–30337.
[39] M. Raphael, V. Lehen'kyi, M. Vandenberghe, B. Beck, S. Khalimonchyk, A.F. Vanden, L.
Farsetti, E. Germain, A. Bokhobza, A. Mihalache, P. Gosset, C. Romanin, P. Clezardin,
R. Skryma, N. Prevarskaya, TRPV6 calcium channel translocates to the plasma mem-
brane via Orai1-mediated mechanism and controls cancer cell survival, Proc. Natl.
Acad. Sci. U. S. A. 111 (2014) E3870–E3879.
[40] D. Yue, Y. Wang, J.Y. Xiao, P. Wang, C.S. Ren, Expression of TRPC6 in benign and ma-
lignant human prostate tissues, Asian J. Androl. 11 (2009) 541–547.
[41] Y. Sun, P. Sukumaran, A. Varma, S. Derry, A.E. Sahmoun, B.B. Singh, Cholesterol-
induced activation of TRPM7 regulates cell proliferation, migration, and viability
of human prostate cells, Biochim. Biophys. Acta 1843 (2014) 1839–1850.
[42] K. Pelton, M.R. Freeman, K.R. Solomon, Cholesterol and prostate cancer, Curr. Opin.
Pharmacol. 12 (2012) 751–759.
[43] L. Tsavaler, M.H. Shapero, S. Morkowski, R. Laus, Trp-p8, a novel prostate-speciﬁc
gene, is up-regulated in prostate cancer and other malignancies and shares high ho-
mology with transient receptor potential calcium channel proteins, Cancer Res. 61
(2001) 3760–3769.
[44] L. Zhang, G.J. Barritt, TRPM8 in prostate cancer cells: a potential diagnostic and prog-
nostic marker with a secretory function? Endocr. Relat. Cancer 13 (2006) 27–38.
[45] L. Zhang, G.J. Barritt, Evidence that TRPM8 is an androgen-dependent Ca2+ channel
required for the survival of prostate cancer cells, Cancer Res. 64 (2004) 8365–8373.
[46] C. Dubois, A.F. Vanden, V. Lehen'kyi, D. Gkika, B. Guarmit, G. Lepage, C. Slomianny,
A.S. Borowiec, G. Bidaux, M. Benahmed, Y. Shuba, N. Prevarskaya, Remodeling of
channel-forming ORAI proteins determines an oncogenic switch in prostate cancer,
Cancer Cell 26 (2014) 19–32.
[47] R. Chen, X. Zeng, R. Zhang, J. Huang, X. Kuang, J. Yang, J. Liu, O. Tawﬁk, J.B. Thrasher,
B. Li, Cav1.3 channel alpha1D protein is overexpressed and modulates androgen re-
ceptor transactivation in prostate cancers, Urol. Oncol. 32 (2014) 524–536.
[48] D.M. Haverstick, T.N. Heady, T.L. Macdonald, L.S. Gray, Inhibition of human prostate
cancer proliferation in vitro and in a mouse model by a compound synthesized to
block Ca2+ entry, Cancer Res. 60 (2000) 1002–1008.
[49] P. Mariot, K. Vanoverberghe, N. Lalevee, M.F. Rossier, N. Prevarskaya, Overexpres-
sion of an alpha 1H (Cav3.2) T-type calcium channel during neuroendocrine differ-
entiation of human prostate cancer cells, J. Biol. Chem. 277 (2002) 10824–10833.
[50] I. Azimi, S.J. Roberts-Thomson, G.R. Monteith, Calcium inﬂux pathways in breast
cancer: opportunities for pharmacological intervention, Br. J. Pharmacol. 171
(2014) 945–960.
[51] J. Chen, Y. Luan, R. Yu, Z. Zhang, J. Zhang, W. Wang, Transient receptor potential
(TRP) channels, promising potential diagnostic and therapeutic tools for cancer,
Biosci. Trends 8 (2014) 1–10.
[52] L. Zhuang, J.B. Peng, L. Tou, H. Takanaga, R.M. Adam, M.A. Hediger, M.R. Freeman,
Calcium-selective ion channel, CaT1, is apically localized in gastrointestinal tractepithelia and is aberrantly expressed in human malignancies, Lab. Investig. 82
(2002) 1755–1764.
[53] V. Lehen'kyi, M. Raphael, N. Prevarskaya, The role of the TRPV6 channel in cancer, J.
Physiol. 590 (2012) 1369–1376.
[54] K.A. Bolanz, M.A. Hediger, C.P. Landowski, The role of TRPV6 in breast carcinogene-
sis, Mol. Cancer Ther. 7 (2008) 271–279.
[55] I. Dhennin-Duthille, M. Gautier, M. Faouzi, A. Guilbert, M. Brevet, D. Vaudry, A.
Ahidouch, H. Sevestre, H. Ouadid-Ahidouch, High expression of transient receptor
potential channels in human breast cancer epithelial cells and tissues: correlation
with pathological parameters, Cell. Physiol. Biochem. 28 (2011) 813–822.
[56] A.A. Peters, P.T. Simpson, J.J. Bassett, J.M. Lee, S.L. Da, L.E. Reid, S. Song, M.O. Parat,
S.R. Lakhani, P.A. Kenny, S.J. Roberts-Thomson, G.R. Monteith, Calcium channel
TRPV6 as a potential therapeutic target in estrogen receptor-negative breast cancer,
Mol. Cancer Ther. 11 (2012) 2158–2168.
[57] S.Y. Kim, D. Yang, J. Myeong, K. Ha, S.H. Kim, E.J. Park, I.G. Kim, N.H. Cho, K.P. Lee, J.H.
Jeon, I. So, Regulation of calcium inﬂux and signaling pathway in cancer cells via
TRPV6–Numb1 interaction, Cell Calcium 53 (2013) 102–111.
[58] E. Aydar, S. Yeo, M. Djamgoz, C. Palmer, Abnormal expression, localization and inter-
action of canonical transient receptor potential ion channels in human breast cancer
cell lines and tissues: a potential target for breast cancer diagnosis and therapy,
Cancer Cell Int. 9 (2009) 23.
[59] H.Y. El, A. Ahidouch, M. Roudbaraki, S. Guenin, G. Brule, H. Ouadid-Ahidouch,
Calcium-sensing receptor stimulation induces nonselective cation channel activa-
tion in breast cancer cells, J. Membr. Biol. 211 (2006) 127–137.
[60] H.Y. El, A. Ahidouch, V. Lehen'kyi, F. Hague, F. Gouilleux, R. Mentaverri, S. Kamel, K.
Lassoued, G. Brule, H. Ouadid-Ahidouch, Extracellular signal-regulated kinases 1 and
2 and TRPC1 channels are required for calcium-sensing receptor-stimulated MCF-7
breast cancer cell proliferation, Cell. Physiol. Biochem. 23 (2009) 335–346.
[61] A. Guilbert, M. Gautier, I. Dhennin-Duthille, N. Haren, H. Sevestre, H. Ouadid-
Ahidouch, Evidence that TRPM7 is required for breast cancer cell proliferation,
Am. J. Physiol. Cell Physiol. 297 (2009) C493–C502.
[62] D. McAndrew, D.M. Grice, A.A. Peters, F.M. Davis, T. Stewart, M. Rice, C.E. Smart, M.A.
Brown, P.A. Kenny, S.J. Roberts-Thomson, G.R. Monteith, ORAI1-mediated calcium
inﬂux in lactation and in breast cancer, Mol. Cancer Ther. 10 (2011) 448–460.
[63] M. Feng, D.M. Grice, H.M. Faddy, N. Nguyen, S. Leitch, Y. Wang, S. Muend, P.A. Kenny,
S. Sukumar, S.J. Roberts-Thomson, G.R. Monteith, R. Rao, Store-independent activa-
tion of Orai1 by SPCA2 in mammary tumors, Cell 143 (2010) 84–98.
[64] H.N. Jiang, B. Zeng, Y. Zhang, N. Daskoulidou, H. Fan, J.M. Qu, S.Z. Xu, Involvement of
TRPC channels in lung cancer cell differentiation and the correlation analysis in
human non-small cell lung cancer, PLoS ONE 8 (2013) e67637.
[65] N. Tajeddine, P. Gailly, TRPC1 protein channel is major regulator of epidermal
growth factor receptor signaling, J. Biol. Chem. 287 (2012) 16146–16157.
[66] A.S. Ay, N. Benzerdjerb, H. Sevestre, A. Ahidouch, H. Ouadid-Ahidouch, Orai3 consti-
tutes a native store-operated calcium entry that regulates non small cell lung adeno-
carcinoma cell proliferation, PLoS ONE 8 (2013) e72889.
[67] M.F. Hou, H.C. Kuo, J.H. Li, Y.S. Wang, C.C. Chang, K.C. Chen, W.C. Chen, C.C. Chiu, S.
Yang, W.C. Chang, Orai1/CRACM1 overexpression suppresses cell proliferation via
attenuation of the store-operated calcium inﬂux-mediated signalling pathway in
A549 lung cancer cells, Biochim. Biophys. Acta 1810 (2011) 1278–1284.
[68] R.K. Motiani, I.F. Abdullaev, M. Trebak, A novel native store-operated calcium chan-
nel encoded by Orai3: selective requirement of Orai3 versus Orai1 in estrogen
receptor-positive versus estrogen receptor-negative breast cancer cells, J. Biol.
Chem. 285 (2010) 19173–19183.
[69] M. Prakriya, S. Feske, Y. Gwack, S. Srikanth, A. Rao, P.G. Hogan, Orai1 is an essential
pore subunit of the CRAC channel, Nature 443 (2006) 230–233.
[70] K.T. Cheng, X. Liu, H.L. Ong, W. Swaim, I.S. Ambudkar, Local Ca(2)+ entry via Orai1
regulates plasma membrane recruitment of TRPC1 and controls cytosolic Ca(2)+
signals required for speciﬁc cell functions, PLoS Biol. 9 (2011) e1001025.
[71] T.J. Shuttleworth, Orai3—the ‘exceptional’ Orai? J. Physiol. 590 (2012) 241–257.
[72] C. Wei, X. Wang, M. Chen, K. Ouyang, M. Zheng, H. Cheng, Flickering calciummicro-
domains signal turning of migrating cells, Can. J. Physiol. Pharmacol. 88 (2010)
105–110.
[73] C. Wei, X. Wang, M. Chen, K. Ouyang, L.S. Song, H. Cheng, Calcium ﬂickers steer cell
migration, Nature 457 (2009) 901–905.
[74] M. Monet, V. Lehen'kyi, F. Gackiere, V. Firlej, M. Vandenberghe, M. Roudbaraki, D.
Gkika, A. Pourtier, G. Bidaux, C. Slomianny, P. Delcourt, F. Rassendren, J.P. Bergerat,
J. Ceraline, F. Cabon, S. Humez, N. Prevarskaya, Role of cationic channel TRPV2 in
promoting prostate cancer migration and progression to androgen resistance, Can-
cer Res. 70 (2010) 1225–1235.
[75] M. Monet, D. Gkika, V. Lehen'kyi, A. Pourtier, A.F. Vanden, G. Bidaux, V. Juvin, F.
Rassendren, S. Humez, N. Prevarsakaya, Lysophospholipids stimulate prostate can-
cer cell migration via TRPV2 channel activation, Biochim. Biophys. Acta 1793
(2009) 528–539.
[76] A. Oulidi, A. Bokhobza, D. Gkika, A.F. Vanden, V. Lehen'kyi, L. Ouaﬁk, B. Mauroy, N.
Prevarskaya, TRPV2mediates adrenomedullin stimulation of prostate and urothelial
cancer cell adhesion, migration and invasion, PLoS ONE 8 (2013) e64885.
[77] S. Yang, J.J. Zhang, X.Y. Huang, Orai1 and STIM1 are critical for breast tumor cell mi-
gration and metastasis, Cancer Cell 15 (2009) 124–134.
[78] D. Gkika, M. Flourakis, L. Lemonnier, N. Prevarskaya, PSA reduces prostate cancer
cell motility by stimulating TRPM8 activity and plasma membrane expression, On-
cogene 29 (2010) 4611–4616.
[79] S. Derouiche, M.Warnier, P. Mariot, P. Gosset, B. Mauroy, J.L. Bonnal, C. Slomianny, P.
Delcourt, N. Prevarskaya, M. Roudbaraki, Bisphenol A stimulates human prostate
cancer cell migration remodelling of calcium signalling, SpringerPlus 2 (2013) 54.
[80] C. Palmieri, B. Rudraraju, M. Monteverde, L. Lattanzio, O. Gojis, R. Brizio, O. Garrone,
M. Merlano, N. Syed, N.C. Lo, T. Crook, Methylation of the calcium channel regulatory
2522 N. Déliot, B. Constantin / Biochimica et Biophysica Acta 1848 (2015) 2512–2522subunit alpha2delta-3 (CACNA2D3) predicts site-speciﬁc relapse in oestrogen
receptor-positive primary breast carcinomas, Br. J. Cancer 107 (2012) 375–381.
[81] R.K. Motiani, X. Zhang, K.E. Harmon, R.S. Keller, K. Matrougui, J.A. Bennett, M. Trebak,
Orai3 is an estrogen receptor alpha-regulated Ca(2)(+) channel that promotes tu-
morigenesis, FASEB J. 27 (2013) 63–75.
[82] M. Hammadi, V. Chopin, F. Matifat, I. Dhennin-Duthille, M. Chasseraud, H. Sevestre,
H. Ouadid-Ahidouch, Human ether a-gogo K(+) channel 1 (hEag1) regulates MDA-
MB-231 breast cancer cell migration through Orai1-dependent calcium entry, J. Cell.
Physiol. 227 (2012) 3837–3846.
[83] A. Chantome, M. Potier-Cartereau, L. Clarysse, G. Fromont, S. Marionneau-Lambot,
M. Gueguinou, J.C. Pages, C. Collin, T. Oullier, A. Girault, F. Arbion, J.P. Haelters, P.A.
Jaffres, M. Pinault, P. Besson, V. Joulin, P. Bougnoux, C. Vandier, Pivotal role of the
lipid Raft SK3–Orai1 complex in human cancer cell migration and bone metastases,
Cancer Res. 73 (2013) 4852–4861.
[84] X. Meng, C. Cai, J. Wu, S. Cai, C. Ye, H. Chen, Z. Yang, H. Zeng, Q. Shen, F. Zou, TRPM7
mediates breast cancer cell migration and invasion through the MAPK pathway,
Cancer Lett. 333 (2013) 96–102.[85] A. Guilbert, M. Gautier, I. Dhennin-Duthille, P. Rybarczyk, J. Sahni, H. Sevestre, A.M.
Scharenberg, H. Ouadid-Ahidouch, Transient receptor potential melastatin 7 is in-
volved in oestrogen receptor-negative metastatic breast cancer cells migration
through its kinase domain, Eur. J. Cancer 49 (2013) 3694–3707.
[86] H. Zhang, L. Zhou, W. Shi, N. Song, K. Yu, Y. Gu, A mechanism underlying the effects
of polyunsaturated fatty acids on breast cancer, Int. J. Mol. Med. 30 (2012) 487–494.
[87] H. Gao, X. Chen, X. Du, B. Guan, Y. Liu, H. Zhang, EGF enhances the migration of can-
cer cells by up-regulation of TRPM7, Cell Calcium 50 (2011) 559–568.
[88] M. Flourakis, V. Lehen'kyi, B. Beck, M. Raphael, M. Vandenberghe, F.V. Abeele, M.
Roudbaraki, G. Lepage, B. Mauroy, C. Romanin, Y. Shuba, R. Skryma, N. Prevarskaya,
Orai1 contributes to the establishment of an apoptosis-resistant phenotype in pros-
tate cancer cells, Cell Death Dis. 1 (2010) e75.
[89] A. Djillani, I. Doignon, T. Luyten, B. Lamkhioued, S.C. Gangloff, J.B. Parys, O. Nusse, C.
Chomienne, O. Dellis, Potentiation of the store-operated calcium entry (SOCE) in-
duces phytohemagglutinin-activated Jurkat T cell apoptosis, Cell Calcium (2015)
[Epub ahead of print].
